articleThe LancetMar 1, 2002Closed access

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Sahlgrenska University Hospital · NewYork–Presbyterian Hospital · +13 more institutions

Indexed incrossref

Abstract

No abstract available for this paper.

Citation impact

5,415
total citations
FWCI
302.91
Percentile
100%
References
29
Citations per year

Authors

15

Topics & keywords

Keywords
  • Atenolol
  • Medicine
  • Losartan
  • Blood pressure
  • Myocardial infarction
  • Stroke (engine)
  • Cardiology
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.